Literature DB >> 2157241

Mixed müllerian tumours of the uterus--prognostic factors: a clinical and histopathologic study of 147 cases.

B Larson1, C Silfverswärd, B Nilsson, F Pettersson.   

Abstract

One hundred and forty-seven women with uterine mixed Müllerian tumours (UMMT) treated at Radiumhemmet from 1936 through 1981 were reviewed. The prognostic value of clinical and histopathologic data was analysed with bivariate and multivariate techniques. Stage, age and abdominal pain were found to be significant predictors of survival. Surgery and combined radiotherapy (intracavitary + external irradiation) gave in stage I, a lower local failure rate (p = 0.006) and better overall survival (p = 0.001) than surgery in combination with either intracavitary or external irradiation.

Entities:  

Mesh：

Year:  1990        PMID： 2157241     DOI： 10.1016/0167-8140(90)90100-b

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

2.  Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.

Authors:  Kenichi Harano; Akihiro Hirakawa; Mayu Yunokawa; Toshiaki Nakamura; Toyomi Satoh; Tadaaki Nishikawa; Daisuke Aoki; Kimihiko Ito; Kiyoshi Ito; Toru Nakanishi; Nobuyuki Susumu; Kazuhiro Takehara; Yoh Watanabe; Hidemichi Watari; Toshiaki Saito
Journal:  Int J Clin Oncol       Date:  2015-06-18       Impact factor: 3.402

Review 3.  Uterine/female genital sarcomas.

Authors:  M L Hensley
Journal:  Curr Treat Options Oncol       Date:  2000-06

4.  Uterine carcinosarcoma: A 10-year single institution experience.

Authors:  Leana Terblanche; Matthys H Botha
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.